Ratings by Morgan Stanley (Sean Laaman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/31/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/31/2026 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2026 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2026 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/17/2026 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/11/2026 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/27/2026 | MapLight Therapeutics | MPLT | Downgrade | Equalweight (Overweight) |
34.00 (13.31) |
-60.85% | Details | |
| 7/24/2026 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/23/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/23/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 7/20/2026 | Erasca Inc | ERAS | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/25/2026 | Absci Corp. | ABSI | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/24/2026 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 6/22/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 6/16/2026 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 5/26/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2026 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/14/2026 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/14/2026 | Generate Biomedicines | GENB | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2026 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 5/14/2026 | Absci Corp. | ABSI | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/12/2026 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2026 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/8/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2026 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/5/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2026 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/4/2026 | Alector Inc. | ALEC | Maintain | Underweight (N/A) |
|
Details | ||
| 5/1/2026 | Alector Inc. | ALEC | Maintain | Underweight (N/A) |
|
Details | ||
| 4/30/2026 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/27/2026 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
53.18 (64.84) |
21.93% | Details | |
| 4/20/2026 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/26/2026 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/25/2026 | Absci Corp. | ABSI | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/24/2026 | Generate Biomedicines | GENB | New Coverage | Overweight (N/A) |
12.27 (15.79) |
28.69% | Details | |
| 3/16/2026 | Erasca Inc | ERAS | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/2/2026 | Eikon Therapeutics Inc. | EIKN | New Coverage | Overweight (N/A) |
13.64 (10.88) |
-20.23% | Details | |
| 2/25/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/24/2026 | Axsome Therapeutics | AXSM | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/19/2026 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2026 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 2/2/2026 | Exelixis | EXEL | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/29/2026 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2026 | Erasca Inc | ERAS | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/15/2026 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2026 | Absci Corp. | ABSI | Downgrade | Equalweight (Overweight) |
3.90 (8.84) |
126.67% | Details | |
| 1/8/2026 | Axsome Therapeutics | AXSM | Downgrade | Equalweight (Overweight) |
171.88 (202.83) |
18.01% | Details | |
| 1/8/2026 | Exelixis | EXEL | Downgrade | Equalweight (Overweight) |
43.68 (56.89) |
30.24% | Details | |
| 1/7/2026 | BridgeBio Oncology Therapeutics, In | BBOT | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2026 | BridgeBio Pharma | BBIO | New Coverage | Overweight (N/A) |
78.24 (76.57) |
-2.13% | Details | |
| 1/5/2026 | Zenas Biopharma | ZBIO | Downgrade | Equalweight (Overweight) |
34.50 (31.98) |
-7.3% | Details | |
| 12/31/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 12/18/2025 | Certara Inc. | CERT | Maintain | Equalweight (N/A) |
|
Details | ||
| 12/5/2025 | BridgeBio Oncology Therapeutics, In | BBOT | New Coverage | Overweight (N/A) |
11.07 (8.82) |
-20.33% | Details | |
| 12/4/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/24/2025 | MapLight Therapeutics | MPLT | Maintain | Overweight (N/A) |
|
Details | ||
| 11/21/2025 | MapLight Therapeutics | MPLT | New Coverage | Overweight (N/A) |
14.60 (34.00) |
132.88% | Details | |
| 11/17/2025 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/17/2025 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 11/17/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/17/2025 | Absci Corp. | ABSI | Maintain | Overweight (N/A) |
|
Details | ||
| 11/13/2025 | Zenas Biopharma | ZBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2025 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2025 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2025 | Zenas Biopharma | ZBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/21/2025 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 9/30/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2025 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Schrodinger | SDGR | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/18/2025 | Recursion Pharmaceuticals | RXRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/18/2025 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Absci Corp. | ABSI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/18/2025 | Erasca Inc | ERAS | Downgrade | Equalweight (Overweight) |
1.57 (16.76) |
967.52% | Details | |
| 8/6/2025 | Halozyme Therapeutics | HALO | Upgrade | Overweight (Equalweight) |
59.99 (107.72) |
79.56% | Details | |
| 8/5/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2025 | Axsome Therapeutics | AXSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2025 | argenx SE | ARGX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/29/2025 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/28/2025 | Absci Corp. | ABSI | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2025 | Exelixis | EXEL | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2025 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Overweight (N/A) |
|
Details | ||
| 7/3/2025 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Overweight (N/A) |
57.17 (53.18) |
-6.98% | Details | |
| 7/3/2025 | Disc Medicine | IRON | New Coverage | Overweight (N/A) |
53.17 (78.67) |
47.96% | Details | |
| 7/3/2025 | Certara Inc. | CERT | New Coverage | Equalweight (N/A) |
11.49 (8.10) |
-29.5% | Details | |
| 7/3/2025 | Zenas Biopharma | ZBIO | New Coverage | Overweight (N/A) |
10.22 (34.50) |
237.57% | Details | |
| 7/3/2025 | Axsome Therapeutics | AXSM | New Coverage | Overweight (N/A) |
103.91 (202.83) |
95.2% | Details | |
| 7/3/2025 | Recursion Pharmaceuticals | RXRX | New Coverage | Equalweight (N/A) |
5.13 (3.33) |
-35.09% | Details | |
| 7/3/2025 | argenx SE | ARGX | New Coverage | Overweight (N/A) |
542.47 (1028.51) |
89.6% | Details | |
| 7/3/2025 | Schrodinger | SDGR | New Coverage | Equalweight (N/A) |
20.61 (20.84) |
1.12% | Details | |
| 7/3/2025 | Absci Corp. | ABSI | New Coverage | Overweight (N/A) |
2.59 (8.84) |
241.31% | Details | |
| 5/14/2025 | Halozyme Therapeutics | HALO | Downgrade | Equalweight (Overweight) |
66.58 (59.99) |
-9.9% | Details | |
| 3/7/2025 | Denali Therapeutics Inc. | DNLI | New Coverage | Overweight (N/A) |
16.27 (23.27) |
43.02% | Details | |
| 1/27/2025 | Exelixis | EXEL | Upgrade | Overweight (Equalweight) |
34.13 (56.89) |
66.69% | Details | |
| 12/3/2024 | BeiGene, Ltd. | BGNE | New Coverage | Overweight (N/A) |
205.75 (184.71) |
-10.23% | Details | |
| 4/26/2024 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/25/2024 | ResMed | RMD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | ResMed | RMD | Upgrade | Overweight (Equalweight) |
138.73 (231.36) |
66.77% | Details | |
| 8/12/2022 | ResMed | RMD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/4/2021 | ResMed | RMD | Maintain | Equalweight (N/A) |
|
Details | ||
| 8/7/2020 | ResMed | RMD | Downgrade | Equalweight (Overweight) |
202.96 (231.36) |
13.99% | Details |
